{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:02:15Z","timestamp":1792638135787,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81902127"],"award-info":[{"award-number":["81902127"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tyrosine kinase inhibitors have achieved quite spectacular advances in the treatment of chronic myeloid leukemia (CML), but disease progression and drug resistance that related to the T315I mutation, remain major obstacles. Dendritic cell-derived exosomes (Dex) induce NK cell immunity, but have yet to achieve satisfactory clinical efficacy. An approach to potentiate antitumor immunity by inducing both NK- and T-cell activation is urgently needed. Retinoic acid early inducible-1\u03b3 (RAE-1\u03b3), a major ligand of natural killer group 2 member D (NKG2D), plays an important role in NK-cell and T-lymphocyte responses. We generated RAE-1\u03b3 enriched CML-specific Dex (CML-RAE-1\u03b3-Dex) from dendritic cells (DCs) pulsed with lysates of RAE-1\u03b3-expressing CML cells or T315I-mutant CML cells, aiming to simultaneously activate NK cells and T lymphocytes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We generated novel CML-RAE-1\u03b3-Dex vaccines, which expressed RAE-1\u03b3, and were loaded with CML tumor cell lysates. NK cells or T lymphocytes were coincubated with CML-RAE-1\u03b3-Dex vaccines. Flow cytometry was performed to evaluate the activation and proliferation of these immune cells. Cytokine production and cytotoxicity toward CML cells with or without the T315I mutation were detected by ELISPOT, ELISA and LDH assays. CML models induced by BCR-ABL or BCR-ABL\n                      <jats:sup>T315I<\/jats:sup>\n                      were used to determine the immunological function of Dex in vivo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Herein, CML-RAE-1\u03b3-Dex were prepared. CML-RAE-1\u03b3-Dex effectively enhanced the proliferation and effector functions of NK cells, CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, which in turn produced strong anti-CML efficacy in vitro. Moreover, CML-RAE-1\u03b3-Dex-based immunotherapy inhibited leukemogenesis and generated durable immunological memory in CML mouse models. Similar immune responses were also observed with imatinib-resistant CML cells carrying the T315I mutation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This approach based on CML-RAE-1\u03b3-Dex vaccines may be a promising strategy for CML treatment, especially for cases with the T315I mutation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40164-022-00289-8","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T02:03:05Z","timestamp":1654567385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D\/NKG2D-L pathway to kill CML cells with or without T315I mutation"],"prefix":"10.1186","volume":"11","author":[{"given":"Zhuanyun","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenglan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningshu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"issue":"10","key":"289_CR1","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96(10):3343\u201356.","journal-title":"Blood"},{"issue":"11","key":"289_CR2","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994\u20131004.","journal-title":"N Engl J Med"},{"key":"289_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1182\/asheducation-2009.1.461","volume":"2009","author":"D Bixby","year":"2009","unstructured":"Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematol Am Soc Hematol Educ Program. 2009;2009:461\u201376.","journal-title":"Hematol Am Soc Hematol Educ Program."},{"issue":"11","key":"289_CR4","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8(11):1018\u201329.","journal-title":"Lancet Oncol"},{"issue":"3","key":"289_CR5","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ajh.25011","volume":"93","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018;93(3):442\u201359.","journal-title":"Am J Hematol"},{"issue":"1","key":"289_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/imr.12389","volume":"270","author":"NW van de Donk","year":"2016","unstructured":"van de Donk NW, Janmaat ML, Mutis T, Lammerts van Bueren JJ, Ahmadi T, Sasser AK, Lokhorst HM, Parren PW. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev. 2016;270(1):95\u2013112.","journal-title":"Immunol Rev"},{"issue":"1","key":"289_CR7","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13045-019-0817-3","volume":"12","author":"Z Zhao","year":"2019","unstructured":"Zhao Z, Zheng L, Chen W, Weng W, Song J, Ji J. Delivery strategies of cancer immunotherapy: recent advances and future perspectives. J Hematol Oncol. 2019;12(1):126.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"289_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/2162-3619-2-33","volume":"2","author":"Z Li","year":"2013","unstructured":"Li Z, Chen L, Rubinstein MP. Cancer immunotherapy: are we there yet? Exp Hematol Oncol. 2013;2(1):33.","journal-title":"Exp Hematol Oncol"},{"issue":"7","key":"289_CR9","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/cgt.2013.31","volume":"20","author":"M Koldehoff","year":"2013","unstructured":"Koldehoff M, Zakrzewski JL, Beelen DW, Elmaagacli AH. Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells. Cancer Gene Ther. 2013;20(7):421\u20137.","journal-title":"Cancer Gene Ther"},{"issue":"37","key":"289_CR10","doi-asserted-by":"publisher","first-page":"6028","DOI":"10.1016\/j.vaccine.2010.06.085","volume":"28","author":"MR Bui","year":"2010","unstructured":"Bui MR, Hodson V, King T, Leopold D, Dai S, Fiolkoski V, Oakes S, Duke R, Apelian D, Franzusoff A, DeGregori J. Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model. Vaccine. 2010;28(37):6028\u201335.","journal-title":"Vaccine"},{"issue":"1","key":"289_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-020-00939-6","volume":"13","author":"Y Wang","year":"2020","unstructured":"Wang Y, Xiang Y, Xin VW, Wang XW, Peng XC, Liu XQ, Wang D, Li N, Cheng JT, Lyv YN, Cui SZ, Ma Z, Zhang Q, Xin HW. Dendritic cell biology and its role in tumor immunotherapy. J Hematol Oncol. 2020;13(1):107.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"289_CR12","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","volume":"15","author":"S Anguille","year":"2014","unstructured":"Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014;15(7):e257\u201367.","journal-title":"Lancet Oncol"},{"issue":"1","key":"289_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40164-022-00257-2","volume":"11","author":"J Yu","year":"2022","unstructured":"Yu J, Sun H, Cao W, Song Y, Jiang Z. Research progress on dendritic cell vaccines in cancer immunotherapy. Exp Hematol Oncol. 2022;11(1):3.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"289_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1006\/cimm.1996.0139","volume":"170","author":"DI Gabrilovich","year":"1996","unstructured":"Gabrilovich DI, Ciernik IF, Carbone DP. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol. 1996;170(1):101\u201310.","journal-title":"Cell Immunol"},{"issue":"2","key":"289_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1179\/102453309X385241","volume":"14","author":"S Chen","year":"2009","unstructured":"Chen S, Yang L, Chen S, Li Y. TCR zeta chain expression in T cells from patients with CML. Hematology. 2009;14(2):95\u2013100.","journal-title":"Hematology"},{"issue":"4","key":"289_CR16","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1172\/JCI81137","volume":"126","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, Andre F, Amigorena S, Soria JC, Eggermont A, Kroemer G, Zitvogel L. Dendritic cell-derived exosomes for cancer therapy. J Clin Invest. 2016;126(4):1224\u201332.","journal-title":"J Clin Invest"},{"issue":"1","key":"289_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1479-5876-3-10","volume":"3","author":"B Escudier","year":"2005","unstructured":"Escudier B, Dorval T, Chaput N, Andr\u00e9 F, Caby MP, Novault S, Flament C, Leboulaire C, Borg C, Amigorena S, Boccaccio C, Bonnerot C, Dhellin O, Movassagh M, Piperno S, Robert C, Serra V, Valente N, Le Pecq JB, Spatz A, Lantz O, Tursz T, Angevin E, Zitvogel L. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med. 2005;3(1):10.","journal-title":"J Transl Med"},{"issue":"1","key":"289_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1479-5876-3-9","volume":"3","author":"MA Morse","year":"2005","unstructured":"Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, Valente N, Shreeniwas R, Sutton MA, Delcayre A, Hsu DH, Le Pecq JB, Lyerly HK. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med. 2005;3(1):9.","journal-title":"J Transl Med"},{"issue":"4","key":"289_CR19","doi-asserted-by":"publisher","first-page":"e1071008","DOI":"10.1080\/2162402X.2015.1071008","volume":"5","author":"B Besse","year":"2016","unstructured":"Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, Le Chevalier T, Livartoski A, Barlesi F, Laplanche A, Ploix S, Vimond N, Peguillet I, Th\u00e9ry C, Lacroix L, Zoernig I, Dhodapkar K, Dhodapkar M, Viaud S, Soria JC, Reiners KS, Pogge von Strandmann E, V\u00e9ly F, Rusakiewicz S, Eggermont A, Pitt JM, Zitvogel L, Chaput N. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 2016;5(4):e1071008.","journal-title":"Oncoimmunology."},{"key":"289_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1146\/annurev-immunol-041015-055700","volume":"36","author":"MFS Lindenbergh","year":"2018","unstructured":"Lindenbergh MFS, Stoorvogel W. Antigen presentation by extracellular vesicles from professional antigen-presenting cells. Annu Rev Immunol. 2018;36:435\u201359.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"289_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13045-020-00987-y","volume":"13","author":"L Zhu","year":"2020","unstructured":"Zhu L, Sun HT, Wang S, Huang SL, Zheng Y, Wang CQ, Hu BY, Qin W, Zou TT, Fu Y, Shen XT, Zhu WW, Geng Y, Lu L, Jia HL, Qin LX, Dong QZ. Isolation and characterization of exosomes for cancer research. J Hematol Oncol. 2020;13(1):152.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"289_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0022-1759(02)00330-7","volume":"270","author":"HG Lamparski","year":"2002","unstructured":"Lamparski HG, Metha-Damani A, Yao JY, Patel S, Hsu DH, Ruegg C, Le Pecq JB. Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods. 2002;270(2):211\u201326.","journal-title":"J Immunol Methods"},{"key":"289_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz3426","author":"X Wang","year":"2020","unstructured":"Wang X, Xiang Z, Liu Y, Huang C, Pei Y, Wang X, Zhi H, Wong WH, Wei H, Ng IO, Lee PP, Chan GC, Lau YL, Tu W. Exosomes derived from V\u03b42-T cells control Epstein-Barr virus-associated tumors and induce T cell antitumor immunity. Sci Transl Med. 2020. https:\/\/doi.org\/10.1126\/scitranslmed.aaz3426.","journal-title":"Sci Transl Med."},{"issue":"1","key":"289_CR24","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13046-020-01781-x","volume":"39","author":"S Nikfarjam","year":"2020","unstructured":"Nikfarjam S, Rezaie J, Kashanchi F, Jafari R. Dexosomes as a cell-free vaccine for cancer immunotherapy. J Exp Clin Cancer Res. 2020;39(1):258.","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"289_CR25","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/ni854","volume":"3","author":"C Th\u00e9ry","year":"2002","unstructured":"Th\u00e9ry C, Duban L, Segura E, V\u00e9ron P, Lantz O, Amigorena S. Indirect activation of na\u00efve CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol. 2002;3(12):1156\u201362.","journal-title":"Nat Immunol"},{"issue":"3","key":"289_CR26","first-page":"205","volume":"3","author":"S Hao","year":"2006","unstructured":"Hao S, Bai O, Yuan J, Qureshi M, Xiang J. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes. Cell Mol Immunol. 2006;3(3):205\u201311.","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"289_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004942","volume":"4","author":"S Viaud","year":"2009","unstructured":"Viaud S, Terme M, Flament C, Taieb J, Andr\u00e9 F, Novault S, Escudier B, Robert C, Caillat-Zucman S, Tursz T, Zitvogel L, Chaput N. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS ONE. 2009;4(3): e4942.","journal-title":"PLoS ONE"},{"key":"289_CR28","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.R120.002309","volume":"20","author":"A Nelde","year":"2021","unstructured":"Nelde A, Rammensee HG, Walz JS. The peptide vaccine of the future. Mol Cell Proteomics. 2021;20: 100022.","journal-title":"Mol Cell Proteomics"},{"issue":"11","key":"289_CR29","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.4161\/21645515.2014.982996","volume":"10","author":"FE Gonz\u00e1lez","year":"2014","unstructured":"Gonz\u00e1lez FE, Gleisner A, Falc\u00f3n-Beas F, Osorio F, L\u00f3pez MN, Salazar-Onfray F. Tumor cell lysates as immunogenic sources for cancer vaccine design. Hum Vaccin Immunother. 2014;10(11):3261\u20139.","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"289_CR30","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/nri1199","volume":"3","author":"DH Raulet","year":"2003","unstructured":"Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003;3(10):781\u201390.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"289_CR31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/77793","volume":"1","author":"A Diefenbach","year":"2000","unstructured":"Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol. 2000;1(2):119\u201326.","journal-title":"Nat Immunol"},{"issue":"3","key":"289_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/85321","volume":"2","author":"V Groh","year":"2001","unstructured":"Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol. 2001;2(3):255\u201360.","journal-title":"Nat Immunol"},{"issue":"5","key":"289_CR33","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.4049\/jimmunol.175.5.2825","volume":"175","author":"MA Markiewicz","year":"2005","unstructured":"Markiewicz MA, Carayannopoulos LN, Naidenko OV, Matsui K, Burack WR, Wise EL, Fremont DH, Allen PM, Yokoyama WM, Colonna M, Shaw AS. Costimulation through NKG2D enhances murine CD8+ CTL function: similarities and differences between NKG2D and CD28 costimulation. J Immunol. 2005;175(5):2825\u201333.","journal-title":"J Immunol"},{"issue":"41","key":"289_CR34","doi-asserted-by":"publisher","first-page":"16550","DOI":"10.1073\/pnas.1310215110","volume":"110","author":"T Trsan","year":"2013","unstructured":"Trsan T, Busche A, Abram M, Wensveen FM, Lemmermann NA, Arapovic M, Babic M, Tomic A, Golemac M, Brinkmann MM, J\u00e4ger W, Oxenius A, Polic B, Krmpotic A, Messerle M, Jonjic S. Superior induction and maintenance of protective CD8 T cells in mice infected with mouse cytomegalovirus vector expressing RAE-1\u03b3. Proc Natl Acad Sci U S A. 2013;110(41):16550\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"289_CR35","doi-asserted-by":"publisher","first-page":"11521","DOI":"10.1073\/pnas.201238598","volume":"98","author":"A Cerwenka","year":"2001","unstructured":"Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci U S A. 2001;98(20):11521\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"289_CR36","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1016\/j.cellsig.2013.08.023","volume":"25","author":"Y Li","year":"2013","unstructured":"Li Y, Chen X, Shi M, Wang H, Cao W, Wang X, Li C, Feng W. Proteomic-based identification of Apg-2 as a therapeutic target for chronic myeloid leukemia. Cell Signal. 2013;25(12):2604\u201312.","journal-title":"Cell Signal"},{"issue":"4","key":"289_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061858","volume":"8","author":"Y Li","year":"2013","unstructured":"Li Y, Yuan Y, Tao K, Wang X, Xiao Q, Huang Z, Zhong L, Cao W, Wen J, Feng W. Inhibition of BCR\/ABL protein expression by miR-203 sensitizes for imatinib mesylate. PLoS ONE. 2013;8(4): e61858.","journal-title":"PLoS ONE"},{"key":"289_CR38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.canlet.2020.04.010","volume":"482","author":"H Yang","year":"2020","unstructured":"Yang H, Zhou H, Huang Z, Tao K, Huang N, Peng Z, Feng W. Induction of CML-specific immune response through cross-presentation triggered by CTP-mediated BCR-ABL-derived peptides. Cancer Lett. 2020;482:44\u201355.","journal-title":"Cancer Lett"},{"issue":"6","key":"289_CR39","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1189\/jlb.1203626","volume":"75","author":"M Delgado","year":"2004","unstructured":"Delgado M, Reduta A, Sharma V, Ganea D. VIP\/PACAP oppositely affects immature and mature dendritic cell expression of CD80\/CD86 and the stimulatory activity for CD4(+) T cells. J Leukoc Biol. 2004;75(6):1122\u201330.","journal-title":"J Leukoc Biol"},{"key":"289_CR40","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3389\/fimmu.2013.00438","volume":"4","author":"AM Dudek","year":"2013","unstructured":"Dudek AM, Martin S, Garg AD, Agostinis P. Immature, semi-mature, and fully mature dendritic cells: toward a DC-cancer cells interface that augments anticancer immunity. Front Immunol. 2013;4:438.","journal-title":"Front Immunol"},{"issue":"11","key":"289_CR41","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.it.2016.08.010","volume":"37","author":"KL Rock","year":"2016","unstructured":"Rock KL, Reits E, Neefjes J. Present yourself! by MHC class I and MHC class II molecules. Trends Immunol. 2016;37(11):724\u201337.","journal-title":"Trends Immunol"},{"key":"289_CR42","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3389\/fimmu.2017.01124","volume":"8","author":"S Paul","year":"2017","unstructured":"Paul S, Lal G. The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. Front Immunol. 2017;8:1124.","journal-title":"Front Immunol"},{"issue":"3","key":"289_CR43","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3109\/08923979909007126","volume":"21","author":"R Marzio","year":"1999","unstructured":"Marzio R, Mau\u00ebl J, Betz-Corradin S. CD69 and regulation of the immune function. Immunopharmacol Immunotoxicol. 1999;21(3):565\u201382.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"10","key":"289_CR44","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.3390\/cancers13102288","volume":"13","author":"K Hashimoto","year":"2021","unstructured":"Hashimoto K. CD137 as an attractive T cell co-stimulatory target in the TNFRSF for immuno-oncology drug development. Cancers (Basel). 2021;13(10):2288.","journal-title":"Cancers (Basel)."},{"issue":"2","key":"289_CR45","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cellimm.2008.08.007","volume":"254","author":"E Aktas","year":"2009","unstructured":"Aktas E, Kucuksezer UC, Bilgic S, Erten G, Deniz G. Relationship between CD107a expression and cytotoxic activity. Cell Immunol. 2009;254(2):149\u201354.","journal-title":"Cell Immunol"},{"issue":"24","key":"289_CR46","doi-asserted-by":"publisher","first-page":"14232","DOI":"10.1128\/JVI.02032-14","volume":"88","author":"K Terahara","year":"2014","unstructured":"Terahara K, Ishii H, Nomura T, Takahashi N, Takeda A, Shiino T, Tsunetsugu-Yokota Y, Matano T. Vaccine-induced CD107a+ CD4+ T cells are resistant to depletion following AIDS virus infection. J Virol. 2014;88(24):14232\u201340.","journal-title":"J Virol"},{"issue":"6","key":"289_CR47","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/nri3839","volume":"15","author":"I Voskoboinik","year":"2015","unstructured":"Voskoboinik I, Whisstock JC, Trapani JA. Perforin and granzymes: function, dysfunction and human pathology. Nat Rev Immunol. 2015;15(6):388\u2013400.","journal-title":"Nat Rev Immunol"},{"issue":"1\u20132","key":"289_CR48","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jim.2003.09.001","volume":"283","author":"AC Karlsson","year":"2003","unstructured":"Karlsson AC, Martin JN, Younger SR, Bredt BM, Epling L, Ronquillo R, Varma A, Deeks SG, McCune JM, Nixon DF, Sinclair E. Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods. 2003;283(1\u20132):141\u201353.","journal-title":"J Immunol Methods"},{"key":"289_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2021.198508","volume":"304","author":"J Zhao","year":"2021","unstructured":"Zhao J, Wang L, Schank M, Dang X, Lu Z, Cao D, Khanal S, Nguyen LN, Nguyen LNT, Zhang J, Zhang Y, Adkins JL, Baird EM, Wu XY, Ning S, Gazzar ME, Moorman JP, Yao ZQ. SARS-CoV-2 specific memory T cell epitopes identified in COVID-19-recovered subjects. Virus Res. 2021;304: 198508.","journal-title":"Virus Res"},{"issue":"1","key":"289_CR50","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1074-7613(02)00258-3","volume":"16","author":"P Li","year":"2002","unstructured":"Li P, McDermott G, Strong RK. Crystal structures of RAE-1beta and its complex with the activating immunoreceptor NKG2D. Immunity. 2002;16(1):77\u201386.","journal-title":"Immunity"},{"key":"289_CR51","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1146\/annurev-immunol-042617-053352","volume":"36","author":"SH Ross","year":"2018","unstructured":"Ross SH, Cantrell DA. Signaling and function of interleukin-2 in T lymphocytes. Annu Rev Immunol. 2018;36:411\u201333.","journal-title":"Annu Rev Immunol"},{"issue":"15","key":"289_CR52","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.3390\/cancers13153667","volume":"13","author":"Y Yao","year":"2021","unstructured":"Yao Y, Fu C, Zhou L, Mi QS, Jiang A. DC-derived exosomes for cancer immunotherapy. Cancers (Basel). 2021;13(15):3667.","journal-title":"Cancers (Basel)."},{"issue":"9","key":"289_CR53","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/ni1236","volume":"6","author":"K Ogasawara","year":"2005","unstructured":"Ogasawara K, Benjamin J, Takaki R, Phillips JH, Lanier LL. Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts. Nat Immunol. 2005;6(9):938\u201345.","journal-title":"Nat Immunol"},{"issue":"Suppl 2","key":"289_CR54","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","volume":"94","author":"M H\u00f6glund","year":"2015","unstructured":"H\u00f6glund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015;94(Suppl 2):S241\u20137.","journal-title":"Ann Hematol"},{"key":"289_CR55","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.actbio.2020.08.008","volume":"115","author":"CD Phung","year":"2020","unstructured":"Phung CD, Pham TT, Nguyen HT, Nguyen TT, Ou W, Jeong JH, Choi HG, Ku SK, Yong CS, Kim JO. Anti-CTLA-4 antibody-functionalized dendritic cell-derived exosomes targeting tumor-draining lymph nodes for effective induction of antitumor T-cell responses. Acta Biomater. 2020;115:371\u201382.","journal-title":"Acta Biomater"},{"issue":"Suppl 4","key":"289_CR56","doi-asserted-by":"publisher","first-page":"iv141","DOI":"10.1093\/annonc\/mdh918","volume":"15","author":"F Andre","year":"2004","unstructured":"Andre F, Escudier B, Angevin E, Tursz T, Zitvogel L. Exosomes for cancer immunotherapy. Ann Oncol. 2004;15(Suppl 4):iv141\u20134.","journal-title":"Ann Oncol"},{"key":"289_CR57","doi-asserted-by":"publisher","first-page":"39071","DOI":"10.1038\/srep39071","volume":"6","author":"Q Zhou","year":"2016","unstructured":"Zhou Q, Zhang Y, Zhao M, Wang X, Ma C, Jiang X, Wu T, Wang D, Zhan L. Mature dendritic cell derived from cryopreserved immature dendritic cell shows impaired homing ability and reduced anti-viral therapeutic effects. Sci Rep. 2016;6:39071.","journal-title":"Sci Rep"},{"issue":"2","key":"289_CR58","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3390\/vaccines3020344","volume":"3","author":"CL Chiang","year":"2015","unstructured":"Chiang CL, Coukos G, Kandalaft LE. Whole tumor antigen vaccines: where are we? Vaccines (Basel). 2015;3(2):344\u201372.","journal-title":"Vaccines (Basel)"},{"issue":"12","key":"289_CR59","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1182\/blood-2008-04-153536","volume":"113","author":"KR Qazi","year":"2009","unstructured":"Qazi KR, Gehrmann U, Domange Jord\u00f6 E, Karlsson MC, Gabrielsson S. Antigen-loaded exosomes alone induce Th1-type memory through a B-cell-dependent mechanism. Blood. 2009;113(12):2673\u201383.","journal-title":"Blood"},{"issue":"2","key":"289_CR60","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.bcmd.2005.05.003","volume":"35","author":"E Segura","year":"2005","unstructured":"Segura E, Amigorena S, Th\u00e9ry C. Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses. Blood Cells Mol Dis. 2005;35(2):89\u201393.","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"289_CR61","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1182\/blood-2005-01-0220","volume":"106","author":"E Segura","year":"2005","unstructured":"Segura E, Nicco C, Lombard B, V\u00e9ron P, Raposo G, Batteux F, Amigorena S, Th\u00e9ry C. ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood. 2005;106(1):216\u201323.","journal-title":"Blood"},{"issue":"16","key":"289_CR62","doi-asserted-by":"publisher","first-page":"9482","DOI":"10.1073\/pnas.95.16.9482","volume":"95","author":"RC Fields","year":"1998","unstructured":"Fields RC, Shimizu K, Mul\u00e9 JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A. 1998;95(16):9482\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"289_CR63","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.4049\/jimmunol.169.3.1236","volume":"169","author":"J Wu","year":"2002","unstructured":"Wu J, Groh V, Spies T. T cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class I-related chains by human epithelial gamma delta T cells. J Immunol. 2002;169(3):1236\u201340.","journal-title":"J Immunol"},{"issue":"10","key":"289_CR64","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.4049\/jimmunol.167.10.5527","volume":"167","author":"AI Roberts","year":"2001","unstructured":"Roberts AI, Lee L, Schwarz E, Groh V, Spies T, Ebert EC, Jabri B. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol. 2001;167(10):5527\u201330.","journal-title":"J Immunol"},{"issue":"7","key":"289_CR65","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1158\/2326-6066.CIR-17-0604","volume":"6","author":"C Borrelli","year":"2018","unstructured":"Borrelli C, Ricci B, Vulpis E, Fionda C, Ricciardi MR, Petrucci MT, Masuelli L, Peri A, Cippitelli M, Zingoni A, Santoni A, Soriani A. Drug-induced senescent multiple myeloma cells elicit NK cell proliferation by direct or exosome-mediated IL15 trans-presentation. Cancer Immunol Res. 2018;6(7):860\u20139.","journal-title":"Cancer Immunol Res"},{"key":"289_CR66","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.biomaterials.2016.07.003","volume":"105","author":"DC Watson","year":"2016","unstructured":"Watson DC, Bayik D, Srivatsan A, Bergamaschi C, Valentin A, Niu G, Bear J, Monninger M, Sun M, Morales-Kastresana A, Jones JC, Felber BK, Chen X, Gursel I, Pavlakis GN. Efficient production and enhanced tumor delivery of engineered extracellular vesicles. Biomaterials. 2016;105:195\u2013205.","journal-title":"Biomaterials"},{"issue":"1","key":"289_CR67","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12176","volume":"11","author":"E Vulpis","year":"2022","unstructured":"Vulpis E, Loconte L, Peri A, Molfetta R, Caracciolo G, Masuelli L, Tomaipitinca L, Peruzzi G, Petillo S, Petrucci MT, Fazio F, Simonelli L, Fionda C, Soriani A, Cerboni C, Cippitelli M, Paolini R, Bernardini G, Palmieri G, Santoni A, Zingoni A. Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: dual role in cancer immunosurveillance. J Extracell Vesicles. 2022;11(1): e12176.","journal-title":"J Extracell Vesicles"},{"issue":"11","key":"289_CR68","doi-asserted-by":"publisher","first-page":"7249","DOI":"10.4049\/jimmunol.180.11.7249","volume":"180","author":"A Clayton","year":"2008","unstructured":"Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z. Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol. 2008;180(11):7249\u201358.","journal-title":"J Immunol"},{"issue":"1","key":"289_CR69","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.0105-2896.2010.00893.x","volume":"235","author":"M Champsaur","year":"2010","unstructured":"Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev. 2010;235(1):267\u201385.","journal-title":"Immunol Rev"},{"issue":"12","key":"289_CR70","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","volume":"129","author":"TL Holyoake","year":"2017","unstructured":"Holyoake TL, Vetrie D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood. 2017;129(12):1595\u2013606.","journal-title":"Blood"},{"issue":"5","key":"289_CR71","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s11912-012-0247-7","volume":"14","author":"T Liu-Dumlao","year":"2012","unstructured":"Liu-Dumlao T, Kantarjian H, Thomas DA, O\u2019Brien S, Ravandi F. Philadelphia-positive acute lymphoblastic leukemia: current treatment options. Curr Oncol Rep. 2012;14(5):387\u201394.","journal-title":"Curr Oncol Rep"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-022-00289-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-022-00289-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-022-00289-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T08:22:30Z","timestamp":1654590150000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-022-00289-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["289"],"URL":"https:\/\/doi.org\/10.1186\/s40164-022-00289-8","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]},"assertion":[{"value":"25 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All work involving animal research were compliant with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No.8023, revised 1978) and performed with the approval of the Ethics Committee of Chongqing Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}